By Chloé Nefdt, Professional Nurse & Founder of IVgo
If you've spent more than fifteen minutes researching peptides online, you've probably encountered at least three of the following: a bodybuilder on YouTube calling something "literally the fountain of youth," a Reddit thread where someone claims a peptide cured their knee, their gut, their marriage, and possibly their dog - and an Instagram ad for a peptide brand whose website has more red flags than a Chinese embassy.
Peptides are genuinely exciting. Some of them are backed by serious research. Others are riding a wave of hype that's about two peer-reviewed papers wide. And the gap between what the internet says peptides can do and what the evidence actually supports is large enough to park a bus in.
So here's what I've done: I've ranked the five peptides that come up most often in conversations about recovery and longevity, and I've been honest about the evidence behind each one. Where the research is strong, I'll tell you. Where it's thin, I'll tell you that too. And I'll be clear about which ones IVgo offers, which ones we don't, and why.
I'm Chloé Nefdt - a SANC-registered Professional Nurse and the founder of IVgo, a mobile health service in Cape Town offering IV therapy, NAD+, and medically supervised peptide therapy. I don't sell hype. I administer protocols with proper medical oversight and pharmacy-compounded formulations. This guide is the honest version of the listicle the internet keeps trying to sell you.
A Quick Primer: What Are Peptides?
Peptides are short chains of amino acids - the same building blocks that make up proteins, just shorter. Your body produces thousands of them naturally. They act as signalling molecules: telling cells when to repair, when to grow, when to reduce inflammation, when to release hormones.
Therapeutic peptides are synthetic versions of these natural compounds, designed to amplify specific biological processes. Some promote tissue repair. Some stimulate growth hormone release. Some target skin regeneration or cellular ageing. The key difference between peptides and hormones or steroids is that peptides generally signal your body to do what it already does - they don't override your biology, they nudge it.
Why do they matter for recovery and longevity? Because as we age, many of these natural peptide signals weaken. Healing slows. Cellular maintenance becomes less efficient. Inflammation accumulates. The premise of peptide therapy is to restore or enhance these signals - and for some peptides, the evidence supporting this premise is genuinely compelling.
For others, not so much. Let's get into it.
1. BPC-157 (Body Protection Compound-157)
Primary use: Tissue repair, gut healing, tendon recovery, anti-inflammatory support
Evidence strength: Strong preclinical - 100+ peer-reviewed studies. Limited human data.
IVgo availability: Yes - R3,000 pre-loaded pen
If I had to pick one peptide that earns its reputation, it's BPC-157. Not because it's a miracle compound - it isn't - but because the volume and consistency of the preclinical research is genuinely impressive.
BPC-157 is a 15-amino-acid synthetic peptide derived from a protective protein found naturally in human gastric juice. It was first studied by Professor Predrag Sikiric and his team at the University of Zagreb in the 1990s, and they've since published over 100 peer-reviewed papers on it. That's not an influencer's supplement line - that's three decades of university research.
What the research shows
Tissue and muscle repair. Staresinic et al. (2006, Journal of Physiology and Pharmacology) demonstrated that BPC-157 significantly improved healing of transected quadriceps muscles in rats - better collagen organisation, faster functional recovery. If you're dealing with a muscle injury that's dragging its feet, this is relevant data.
Tendon healing. Tendons heal slowly because they have poor blood supply. Chang et al. (2011, Journal of Orthopaedic Research) showed BPC-157 promoted tendon-to-bone healing by stimulating growth hormone receptor expression and fibroblast proliferation. Krivic et al. (2006) demonstrated accelerated Achilles tendon healing. For anyone nursing a tendinopathy that physio improved but never fully fixed, this is the peptide that keeps coming up in the literature - for good reason.
Gut healing. Given BPC-157's gastric origins, its effects on the gut are among the most extensively studied. Sikiric et al. have published comprehensively on its protective effects against NSAID-induced lesions, inflammatory bowel disease models, and stress-induced ulcers. A 2018 review in Current Pharmaceutical Design summarised its ability to promote angiogenesis in damaged gut tissue.
Anti-inflammatory modulation. BPC-157 doesn't just suppress inflammation - it modulates it, influencing nitric oxide pathways and reducing pro-inflammatory cytokines while supporting balanced repair. Sikiric et al. (2014) described this as a "Robert cytoprotection" effect: a broad protective mechanism extending beyond the gut.
The honest caveat
The overwhelming majority of BPC-157 research has been conducted in animal models. Human clinical trials are underway but still limited. A 2025 systematic review by Vasireddi et al. in the American Journal of Sports Medicine analysed 36 studies and found 35 were preclinical. The results are consistently promising. The human evidence is still catching up.
This is why BPC-157 sits at the top of my list: not because the evidence is complete, but because the volume, consistency, and mechanistic logic of the preclinical data put it well ahead of most other peptides in this space.
IVgo offers BPC-157 as a pre-loaded pen at R3,000, covering two 6-week treatment cycles. Every client undergoes a consultation with blood work reviewed by a doctor before starting. Read the full deep dive: BPC-157 in South Africa: A Nurse's Complete Guide.
2. TB-500 (Thymosin Beta-4)
Primary use: Systemic tissue repair, cell migration, structural recovery
Evidence strength: Substantial preclinical, some human trials (ophthalmology, wound healing)
IVgo availability: Yes - as part of the Wolverine Stack, R4,500 pre-loaded pen
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino-acid peptide that occurs naturally in nearly all human cells. Your body already produces it - it's found at high concentrations in wound fluid, blood platelets, and white blood cells. When you injure yourself, Thymosin Beta-4 is one of the first molecules deployed to the scene.
The foundational research here is serious. Bock-Marquette et al. (2004) published in Nature - and if you're unfamiliar with the journal hierarchy, Nature is the Champions League of scientific publishing. Their work demonstrated that Thymosin Beta-4 activates integrin-linked kinase (ILK), promotes cardiac cell migration and survival, and significantly improved cardiac function after coronary artery ligation in mice.
What makes TB-500 different from BPC-157
Where BPC-157 works primarily through angiogenesis (building new blood vessels) and local inflammatory modulation, TB-500 works through actin regulation - managing the structural proteins that cells need to move and rebuild. It's the difference between building roads to the construction site (BPC-157) and sending in the workers and materials (TB-500).
Sosne et al. (2007, Clinical Ophthalmology) demonstrated TB-500's ability to accelerate corneal wound healing through enhanced cell migration - and this was one of the few studies conducted in human tissue models, giving it a slightly different evidence profile from many other peptides in the recovery space.
TB-500 also demonstrates potent anti-inflammatory effects through NF-κB signalling inhibition, and emerging research suggests it can mobilise endogenous stem and progenitor cells to sites of damage (Kleinman and Sosne, 2016, Vitamins and Hormones).
Why IVgo pairs it with BPC-157
I don't offer TB-500 as a standalone. At IVgo, it's available as part of the Wolverine Stack - the combination of BPC-157 and TB-500 in a single pre-loaded pen. The rationale is mechanistic: these two peptides address different rate-limiting steps in the healing process. BPC-157 handles vascularisation and inflammation. TB-500 handles cell migration, structural repair, and stem cell recruitment. Together, they cover more phases of tissue repair than either peptide alone.
The Wolverine Stack is priced at R4,500 for a pre-loaded pen covering two 6-week cycles, with the same medical oversight as our BPC-157 programme. Full breakdown here: The Wolverine Stack Explained: BPC-157 + TB-500 for Recovery.
3. GHK-Cu (Copper Peptide)
Primary use: Skin regeneration, wound healing, anti-ageing (primarily skin)
Evidence strength: Decent human data for topical use. Limited evidence for injectable.
IVgo availability: Not currently
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first identified in human plasma by Pickart and Thaler in 1973. It's found in saliva, urine, and blood plasma, with concentrations declining significantly with age - which immediately caught the attention of the anti-ageing research community.
Where the evidence is solid
Topical skin applications. This is GHK-Cu's strongest suit. Pickart et al. (2012, BioMed Research International) reviewed the evidence for GHK-Cu's ability to stimulate collagen synthesis, promote decorin production, and enhance wound healing when applied topically. Multiple studies have demonstrated improvements in skin thickness, elasticity, and appearance with topical GHK-Cu formulations. If you've seen "copper peptide serums" in the skincare aisle, this is the molecule they're based on - and unlike many skincare ingredients, this one actually has a reasonable evidence base.
Wound healing. Leyden et al. (2001) demonstrated that topical GHK-Cu significantly accelerated wound closure in human subjects compared to controls. The mechanism involves stimulating glycosaminoglycan synthesis, small proteoglycan production, and angiogenesis.
Where I pump the brakes
The leap from "topical copper peptide helps skin" to "injectable GHK-Cu reverses ageing" is significantly larger than most peptide websites acknowledge. The injectable form has far less published human data. The systemic effects of injecting GHK-Cu - beyond what happens when you rub it on skin - are not well characterised in clinical studies.
There's also interesting preclinical work suggesting GHK-Cu may influence gene expression broadly, potentially suppressing genes associated with tissue destruction and inflammation. But "interesting preclinical work" and "ready for clinical recommendation" are very different things.
Why IVgo doesn't offer it (yet)
I'm genuinely interested in GHK-Cu, but I won't add a peptide to our menu until the evidence for the specific route of administration I'd be offering meets my threshold. For topical GHK-Cu, the evidence is there - and a good dermatologist or aesthetics practitioner can guide you. For injectable GHK-Cu as a systemic anti-ageing intervention? The research isn't mature enough for me to stand behind it confidently. If that changes, I'll revisit.
4. CJC-1295 / Ipamorelin
Primary use: Growth hormone secretagogues - stimulate natural GH release
Evidence strength: Human clinical data exists. Used widely in anti-ageing medicine.
IVgo availability: Not currently
WADA status: Prohibited (S2 - Peptide Hormones, Growth Factors)
This combination is probably the most widely prescribed peptide protocol in the anti-ageing and longevity clinic space globally. CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue, while Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist. Together, they stimulate your pituitary gland to release more of its own growth hormone - mimicking the natural pulsatile pattern of GH secretion rather than introducing exogenous GH directly.
What the evidence supports
CJC-1295 has actual human pharmacokinetic data. Teichman et al. (2006, The Journal of Clinical Endocrinology & Metabolism) demonstrated that CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 levels in healthy subjects, with a prolonged half-life allowing once- or twice-weekly dosing. This is real clinical data, published in a respected endocrinology journal.
Ipamorelin has been studied in multiple human contexts. Gobburu et al. (1999, Journal of Pharmacology and Experimental Therapeutics) characterised its selective GH-releasing properties - notably, it stimulates GH release without significantly affecting cortisol, prolactin, or ACTH, which makes it cleaner than older secretagogues like GHRP-6.
The reported benefits in clinical practice include improved body composition, better sleep quality, enhanced recovery from training, and improvements in skin quality and general vitality. These are consistent with what you'd expect from optimised growth hormone levels.
The honest complications
The growth hormone space is genuinely complicated, and I think the peptide community doesn't talk about this enough.
Long-term GH elevation has trade-offs. Growth hormone promotes cellular growth - which is great for recovery and tissue repair, but also raises legitimate questions about long-term cancer risk. The relationship between IGF-1 levels and cancer incidence is actively studied and debated. This doesn't mean GH secretagogues cause cancer - but it does mean that chronic, unsupervised elevation of GH/IGF-1 warrants caution and proper medical monitoring.
Diminishing returns and dependency concerns. Extended use of secretagogues can lead to receptor desensitisation. Cycling protocols exist for this reason, but the optimal approach is still being refined.
WADA prohibition. Both CJC-1295 and Ipamorelin are prohibited under WADA's S2 category at all times, in and out of competition. If you compete in any SAIDS-regulated sport, these are completely off limits.
Why IVgo doesn't offer it (currently)
This isn't a quality concern - the compounds themselves are well characterised. It's a scope-of-practice and monitoring question. GH secretagogue therapy requires ongoing blood work (IGF-1, glucose, insulin, thyroid function), regular clinical reassessment, and a level of endocrine monitoring that goes beyond what I currently offer at IVgo. If I were to add it, it would need to be in partnership with an endocrinologist or anti-ageing physician who can provide that oversight properly. I'd rather not offer it than offer it without the full monitoring framework it requires.
5. Epithalon (Epitalon)
Primary use: Telomerase activation, potential longevity peptide
Evidence strength: Limited - primarily from one research group. Fascinating concept, thin evidence.
IVgo availability: Not currently
Epithalon is the synthetic version of epithalamin, a peptide produced by the pineal gland. It was developed and studied primarily by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, and its proposed mechanism is genuinely captivating: it activates telomerase, the enzyme responsible for maintaining telomere length.
Why people are excited about it
Telomeres - the protective caps on the ends of your chromosomes - shorten with each cell division. When they get too short, cells stop dividing or die, which is one of the fundamental mechanisms of biological ageing. If you could maintain telomere length, the theory goes, you could slow or partially reverse cellular ageing.
Khavinson et al. (2003, Bulletin of Experimental Biology and Medicine) reported that epithalamin increased telomerase activity in human somatic cells. A separate study (Khavinson and Morozov, 2003, Neuroendocrinology Letters) reported increased lifespan in mice treated with epithalamin. The same group published a small human study suggesting improvements in melatonin production and immune function in elderly subjects.
Why I'm not convinced (yet)
I'll be straightforward: the evidence base for Epithalon is significantly thinner than for BPC-157 or TB-500, and it comes with some methodological concerns.
Single research group. The vast majority of Epithalon research comes from Khavinson's group. Independent replication by other laboratories is limited. In science, a finding isn't considered robust until multiple independent groups can reproduce it. That hasn't happened at scale for Epithalon.
Publication quality. Much of the research was published in journals with limited international peer review or in Russian-language publications that are difficult to assess for methodological rigour. This isn't a criticism of Russian science - it's a statement about the importance of transparent, internationally peer-reviewed data.
The telomerase-cancer question. Activating telomerase is a double-edged sword. Cancer cells famously upregulate telomerase to achieve immortality. While Epithalon proponents argue that it works differently in healthy cells than in cancerous ones, the long-term safety data to support this distinction simply doesn't exist yet.
Dose, route, and protocol uncertainty. There's no well-established, clinically validated protocol for Epithalon administration in humans. The dosing you'll find online is largely based on anecdotal practitioner experience, not dose-finding clinical trials.
Why IVgo doesn't offer it
The concept is genuinely fascinating - telomerase activation as an anti-ageing strategy is one of the more scientifically grounded longevity hypotheses out there. But "fascinating concept" and "ready for responsible clinical practice" are different things. The evidence isn't there yet. If independent labs replicate Khavinson's findings and proper human trials establish safety and efficacy, I'll be one of the first to take this seriously. Until then, I'd rather be honest with you than trendy.
Comparison Table
| Peptide | Primary Use | Evidence Strength | WADA Status | IVgo Availability |
|---|---|---|---|---|
| BPC-157 | Tissue repair, gut healing, tendons | Strong preclinical (100+ studies), limited human | Prohibited (S0) | Yes - R3,000 pen |
| TB-500 | Systemic repair, cell migration | Substantial preclinical, some human trials | Prohibited (S2) | Yes - Wolverine Stack, R4,500 |
| GHK-Cu | Skin regeneration, wound healing | Good human data (topical), limited (injectable) | Not prohibited | Not currently |
| CJC-1295 / Ipamorelin | Growth hormone optimisation | Human clinical data exists | Prohibited (S2) | Not currently |
| Epithalon | Telomerase activation, longevity | Limited - mostly single research group | Not specifically listed | Not currently |
How to Choose the Right Peptide (It Depends on Your Goals)
One of the most common questions I get is "which peptide should I take?" - and the answer is almost always "that depends entirely on what you're trying to achieve."
If your goal is injury recovery or tissue repair
BPC-157 is your starting point. It has the most evidence specifically for musculoskeletal healing, tendon repair, and gut recovery. If your injury is complex, chronic, or involves multiple tissue types, the Wolverine Stack (BPC-157 + TB-500) provides broader coverage across different phases of the healing process.
If your goal is skin and anti-ageing (topical)
GHK-Cu has the best evidence for skin-specific applications - but in its topical form. Look for properly formulated copper peptide serums from reputable skincare brands. Injectable GHK-Cu for systemic anti-ageing is a different proposition with much less evidence.
If your goal is body composition, sleep, and general vitality
CJC-1295/Ipamorelin is the most commonly used protocol in this space, but it requires proper endocrine monitoring and is best pursued through a specialist anti-ageing clinic with ongoing blood work oversight. It's also WADA-prohibited if you compete.
If your goal is longevity at the cellular level
Epithalon is the most conceptually appealing option in this category, but the evidence isn't mature enough for me to recommend it. Honestly, if longevity is your primary goal, NAD+ therapy has a stronger and more diverse evidence base for cellular health and ageing - and IVgo offers it.
The Sourcing Problem in South Africa
This is the section I wish I didn't have to write, but it's probably the most important one.
South Africa's peptide market is essentially unregulated. Peptides are not scheduled substances (with some exceptions), but they're also not regulated as approved medicines by SAHPRA. This means anyone can import, repackage, and sell peptides without any quality oversight whatsoever.
What this looks like in practice
- Peptide powders sold through Telegram groups, WhatsApp contacts, and anonymous websites with no verifiable source
- Products labelled as one thing but containing something else entirely - or containing the right peptide at the wrong concentration
- No cold chain management during shipping (many peptides degrade rapidly at room temperature)
- No certificates of analysis, no purity testing, no third-party verification
- Zero accountability if something goes wrong
I've had clients come to me after using peptides sourced from unverified online suppliers. In some cases, they experienced no effect at all - which likely means they received a degraded or incorrectly dosed product. In other cases, they experienced side effects inconsistent with the peptide they thought they were taking. Both outcomes are preventable.
What "properly sourced" looks like
At IVgo, every peptide I administer is compounded by a registered South African compounding pharmacy - a facility licensed by SAHPRA with documented quality control processes. Each formulation comes with verified purity and dosing. The pre-loaded pen format eliminates the reconstitution errors that plague the self-mixing approach.
The price difference between pharmacy-compounded peptides and mystery powder from the internet isn't a premium - it's the cost of actually knowing what you're putting in your body. I'd argue that's the minimum standard, not the luxury option.
Frequently Asked Questions
Can I stack multiple peptides from this list?
In theory, yes - and some practitioners do combine peptides from different categories (e.g., BPC-157 for tissue repair alongside CJC-1295/Ipamorelin for GH optimisation). However, the more compounds you add, the more complex the monitoring requirements become and the less established the safety data is for the specific combination. At IVgo, the only stack I offer is the Wolverine Stack (BPC-157 + TB-500), because that's the combination with the strongest mechanistic rationale and the most clinical observation supporting its use. More isn't always better.
Are peptides legal in South Africa?
Most peptides discussed here - including BPC-157, TB-500, GHK-Cu, and Epithalon - are not scheduled substances under SAHPRA regulations. They're legal to possess and use. However, they're not approved as medicines either, which means they exist in a regulatory grey area. The legality is clear; the regulation is absent. That's precisely why your choice of provider matters so much. For a detailed breakdown: BPC-157 in South Africa: A Nurse's Complete Guide.
How do I know if a peptide is right for me?
Start with a consultation. Not a DM, not a Reddit thread, not a podcast episode - a conversation with a qualified healthcare professional who can assess your health history, goals, contraindications, and whether peptide therapy is appropriate for your specific situation. Some people who come to me for peptides end up being better served by NAD+ therapy, IV vitamin protocols, or a referral to a specialist. That's not a failed sales call - that's responsible healthcare.
What about peptides and cancer risk?
This is an important question that deserves an honest answer. Peptides that promote cell growth, angiogenesis, or telomerase activation carry theoretical concerns regarding cancer - specifically, the worry that promoting cellular proliferation could benefit existing but undetected cancerous cells. The preclinical safety data for BPC-157 and TB-500 hasn't shown tumour-promoting effects, but long-term human safety data is limited. This is exactly why I require blood work and a doctor review before starting any peptide protocol, and why individuals with active cancer or a history of cancer should discuss peptide therapy with their oncologist before proceeding.
Why doesn't IVgo offer all five peptides on this list?
Because my job is to provide treatments I can stand behind with proper medical oversight - not to offer the longest menu. I offer BPC-157 and TB-500 because they have the strongest evidence base for the indications my clients most commonly present with (injury recovery, tissue repair, chronic musculoskeletal conditions), and because I can administer them within a framework of consultation, doctor review, pharmacy-compounded formulations, and ongoing support. The peptides I don't offer either require monitoring beyond my current scope (CJC-1295/Ipamorelin), lack sufficient evidence for the route of administration I'd use (injectable GHK-Cu), or have an evidence base that isn't mature enough for me to recommend responsibly (Epithalon). If and when any of these reach a threshold I'm comfortable with, I'll add them.
The Bottom Line
The peptide space in 2026 is a strange mix of genuine science, premature hype, and outright grift. Some of these compounds - particularly BPC-157 and TB-500 - are backed by substantial preclinical research and growing clinical experience. Others are interesting concepts riding on thin evidence and thick marketing.
Here's my ranking in terms of current evidence strength for their primary indications:
- BPC-157 - the most researched, the most consistent, the best starting point for recovery
- TB-500 - strong mechanistic basis, excellent complement to BPC-157, some human data
- GHK-Cu - solid evidence for topical skin applications, less so for injectable systemic use
- CJC-1295 / Ipamorelin - real human data, but requires proper endocrine monitoring
- Epithalon - fascinating concept, insufficient independent evidence
Your choice of peptide matters less than your choice of provider. A well-sourced, properly supervised BPC-157 protocol will outperform a poorly sourced, unsupervised stack of three peptides every single time. Quality, oversight, and honesty aren't optional extras - they're the foundation.
Ready to explore peptide therapy with proper medical oversight?
Book your consultation with IVgo - Cape Town's mobile IV therapy, NAD+, and peptide service.
Call or WhatsApp 074 604 5555 | Visit ivgo.co.za | Instagram: @ivgo_cape_town
Chloé Nefdt is a SANC-registered Professional Nurse and the founder of IVgo, Cape Town's mobile IV therapy, NAD+ and peptide service. She specialises in evidence-based peptide therapy, NAD+ protocols, and making advanced health interventions accessible - with proper medical oversight - outside the traditional clinic setting.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. The peptides discussed are not approved therapeutic goods in South Africa. The majority of research cited is preclinical (animal models), and human clinical data remains limited for most compounds. Always consult a qualified healthcare professional before starting any new treatment. Athletes subject to WADA or SAIDS testing should be aware that BPC-157, TB-500, CJC-1295, and Ipamorelin are all prohibited substances under current anti-doping regulations.